newsfilter
← Latest News
Business Wire·

Sangamo Therapeutics Reports on Pfizer's Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate

Giroctocogene fitelparvovec trial meets primary and key secondary objectives of superiority compared to prophylaxis Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today reported on Pfizer Inc.'s